3038-47-9

Usage

Uses

Used in Pharmaceutical Industry:
2-(TRIFLUOROMETHYL)PHENYLACETONITRILE is used as a key intermediate in the synthesis of non-peptide CCR1 receptor antagonists. These antagonists are important for the development of drugs targeting various inflammatory and autoimmune diseases, as they help modulate the immune response by blocking the action of certain receptors.
2-(TRIFLUOROMETHYL)PHENYLACETONITRILE is also used as a starting material in the synthesis of cyclopentimidazopyridinone and related compounds, which act as interleukin-6 inhibitors. These inhibitors have potential applications in the treatment of various inflammatory and autoimmune disorders, as well as certain types of cancer.
Used in Chemical Synthesis:
In the field of organic chemistry, 2-(TRIFLUOROMETHYL)PHENYLACETONITRILE is used in the facile synthesis of 1,2,3,4-tetrasubstituted naphthalenes. This is achieved through a condensation reaction with aromatic acetonitriles under basic conditions. The resulting tetrasubstituted naphthalenes have potential applications in various chemical and pharmaceutical industries due to their unique structural properties and potential for further functionalization.

InChI:InChI=1/C9H6F3N/c10-9(11,12)8-4-2-1-3-7(8)5-6-13/h1-4H,5H2

Upstream product

• 395-44-8 o-trifluoromethylbenzyl bromide 
• 151-50-8 potassium cyanide 
• 21742-00-7 2-(trifluoromethyl)benzyl chloride 
• 773837-37-9 sodium cyanide 
• 395-47-1 [2-(trifluoromethyl)phenyl]magnesium bromide 
• 346-06-5 (2-(trifluoromethyl)phenyl)methanol 

Downstream Products

• 29786-42-3 1-(2-(trifluoromethyl)phenyl)cyclobutane-1-carbonitrile 
• 3038-48-0 2-(trifluoromethyl)phenylacetic acid 
• 76574-59-9 6-(2-Trifluoromethyl-phenyl)-pyrido[2,3-d]pyrimidin-7-ylamine 
• 634465-94-4 tert-butyl 4-cyano-4-[2-(trifluoromethyl)phenyl]-1-piperidinecarboxylate 
• 215797-66-3 2-[2-(Trifluoromethyl)phenyl]ethylamine hydrochloride 
• 108439-67-4 3-ethoxy-4-methoxybenzylamine 
• 124276-63-7 1-(2-(trifluoromethyl)phenyl)cyclopropanecarbonitrile 
• 1034694-61-5 2-(2-(trifluoromethyl)phenyl)-3-hydroxypropanenitrile 
• 1241494-93-8 C₁₂H₁₀F₃NO 
• 1233246-24-6 3-(2-(trifluoromethyl)phenyl)-1,8-naphthyridin-2-amine 

Relevant academic research and scientific papers

17a-HYDROXYLASE/C17,20-LYASE INHIBITORS

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.

17α-HYDROXYLASE/C17,20-LYASE INHIBITORS

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.

Anthranilic acid derivatives as inhibitors of the cGMP-phosphodiesterase

Compounds of formula (I) STR1where R 1 is hydrogen; R 2 is nitro, cyano or halo(lower)alkyl; R 3 is phenyl substituted with one or more substituents selected from halogen, cyano and lower alkoxy; A is a lower alkylene group; R 4 is a group CR 6 R 7 R 8 wherein R 6 and R 7 form, together with the carbon atom to which they are attached a cycloalkyl group optionally substituted with hydroxy, lower alkoxy or a lower alkanoylamino; and R 8 is hydrogen; its prodrug and a salt thereof.

Antihypertensive Activity of 6-Arylpyridopyrimidin-7-amine Derivatives

A series of 51 6-arylpyridopyrimidin-7-amine derivatives was prepared and evaluated for antihypertensive activity in the conscious spontaneously hypertensive rat.A number of these compounds, notably 6-(2,6-dichlorophenyl)-2-methylpyridopyrimidin-7-amine (36), lowered blood pressure in these rats in a gradual and sustained manner to normotensive levels at oral doses of 10-50 mg/kg.Normalized blood pressure levels could then be maintained by single daily oral doses.The effect of structural variation in the 6-aryl group and in the 2 and 4 positions of the pyridopyrimidine ring on activity is reported and discussed.

(Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines

This disclosure describes substituted 1,2,4-triazolo[1,5-a]pyrimidines and substituted 1,2,4-triazolo[4,3-a]pyrimidines which possess anxiolytic activity.